Challenges for drug discovery - A case study of urokinase receptor inhibition

Combinatorial Chemistry and High Throughput Screening

Volumn 12, Issue 10, 2009, Pages 961-967

  Chen, Zhuo ^a   Lin, Lin ^b   Huai, Qing ^b   Huang, Mingdong ^b  

^a FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AE 105; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; UROKINASE RECEPTOR INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CYSTADENOCARCINOMA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; DRUG UPTAKE; HUMAN; HYDROPHOBICITY; LIVER METASTASIS; LUNG METASTASIS; NONHUMAN; OVARY CARCINOMA; PANCREAS CARCINOMA; PERITONEUM METASTASIS; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR BLOCKING; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION; TUMOR PROMOTION;

AMINO ACID SEQUENCE; ANIMALS; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HUMANS; HYDROPHOBICITY; LIGANDS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN CONFORMATION; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

MURINAE;

EID: 71249090840     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620709789824727     Document Type: Article

References (54)

1. Drews, J. Drug discovery: a historical perspective. Science, 2000, 287(5460), 1960-1964.
2. Cox, B.; Denyer, J.C.; Binnie, A.; Donnelly, M.C.; Evans, B.; Green, D.V.; Lewis, J.A.; Mander, T.H.; Merritt, A.T.; Valler, M.J.; Watson, S.P. Application of high-throughput screening techniques to drug discovery. Prog. Med. Chem., 2000, 37, 83-133.
3. Andreasen, P.A.; Egelund, R.; Petersen, H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol. Life Sci., 2000, 57(1), 25-40.
4. Ploug, M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr. Pharm. Des., 2003, 9(19), 1499-1528.
5. Behrendt, N. The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. Biol. Chem., 2004, 385(2), 103-136.
6. Blasi, F.; Carmeliet, P. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol., 2002, 3(12), 932-943.
7. Czekay, R.P.; Kuemmel, T.A.; Orlando, R.A.; Farquhar, M.G. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell., 2001, 12(5), 1467-1479.
8. Mazar, A.P. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs, 2001, 12(5), 387-400.
9. Reuning, U.; Sperl, S.; Kopitz, C.; Kessler, H.; Kruger, A.; Schmitt, M.; Magdolen, V. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr. Pharm. Des., 2003, 9(19), 1529-1543.
10. Pillay, V.; Dass, C.R.; Choong, P.F. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol., 2007, 25(1), 33-39. (Pubitemid 46001467)
11. Nielsen, B.S.; Rank, F.; Illemann, M.; Lund, L.R.; Dano, K. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ co-express urokinase and urokinase receptor. Int. J. Cancer, 2007, 120(10), 2086-2095.
12. Pappot, H.; Hoyer-Hansen, G.; Ronne, E.; Hansen, H.H.; Brunner, N.; Dano, K.; Grondahl-Hansen, J. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur. J. Cancer, 1997, 33(6), 867-872.
13. Pedersen, N.; Schmitt, M.; Ronne, E.; Nicoletti, M.I.; Hoyer- Hansen, G.; Conese, M.; Giavazzi, R.; Dano, K.; Kuhn, W.; Janicke, F.; Blasi, F. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J. Clin. Invest., 1993, 92(5), 2160-2167.
14. Stephens, R.W.; Pedersen, A.N.; Nielsen, H.J.; Hamers, M.J.; Hoyer-Hansen, G.; Ronne, E.; Dybkjaer, E.; Dano, K.; Brunner, N. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin. Chem., 1997, 43(10), 1868-1876.
15. Stephens, R.W.; Nielsen, H.J.; Christensen, I.J.; Thorlacius-Ussing, O.; Sørensen, S.; Danø, K.; Brünner, N. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J. Natl. Cancer Inst., 1999, 91(10), 869-874.
16. Foekens, J.A.; Peters, H.A.; Look, M.P.; Portengen, H.; Schmitt, M.; Kramer, M.D.; Brunner, N.; Janicke, F.; Meijer-van Gelder, M.E.; Henzen-Logmans, S.C.; van Putten, W.L.; Klijn, J.G. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res., 2000, 60(3), 636-643. (Pubitemid 30094561)
17. Mohanam, S.; Chintala, S.K.; Mohan, P.M.; Sawaya, R.; Lagos, G.K.; Gokaslan, Z.L.; Kouraklis, G.P.; Rao, J.S. Increased invasion of neuroglioma cells transfected with urokinase plasminogen activator receptor cDNA. Int. J. Oncol., 1998, 13(6), 1285-1290.
18. Kariko, K.; Kuo, A.; Boyd, D.; Okada, S.S.; Cines, D.B.; Barnathan, E.S. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res., 1993, 53(13), 3109-3117.
19. Lyu, M.A.; Choi, Y.K.; Park, B.N.; Kim, B.J.; Park, I.K.; Hyun, B.H.; Kook, Y.H. Over-expression of urokinase receptor in human epidermoid-carcinoma cell line (HEp3) increases tumorigenicity on chorio-allantoic membrane and in severe-combined-immunodeficient mice. Int. J. Cancer, 1998, 77(2), 257-263.
20. Xing, R.H.; Rabbani, S.A. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int. J. Cancer, 1996, 67(3), 423-429.
21. Wilhelm, O.; Weidle, U.; Hohl, S.; Rettenberger, P.; Schmitt, M.; Graeff, H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett., 1994, 337(2), 131-134.
22. Festuccia, C.; Dolo, V.; Guerra, F.; Violini, S.; Muzi, P.; Pavan, A.; Bologna, M. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin. Exp. Metastasis, 1998, 16(6), 513-528.
23. Min, H.Y.; Doyle, L.V.; Vitt, C.R.; Zandonella, C.L.; Stratton- Thomas, J.R.; Shuman, M.A.; Rosenberg, S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res., 1996, 56(10), 2428-2433. (Pubitemid 26154094)
24. Bauer, T.W.; Liu, W.; Fan, F.; Camp, E.R.; Yang, A.; Somcio, R.J.; Bucana, C.D.; Callahan, J.; Parry, G.C.; Evans, D.B.; Boyd, D.D.; Mazar, A.P.; Ellis, L.M. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res., 2005, 65(17), 7775-7781.
25. Bugge, T.H.; Suh, T.T.; Flick, M.J.; Daugherty, C.C.; Romer, J.; Solberg, H.; Ellis, V.; Dano, K.; Degen, J.L. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Chem., 1995, 270(28), 16886-16894.
26. Stoppelli, M.P.; Corti, A.; Soffientini, A.; Cassani, G.; Blasi, F.; Assoian, R.K. Differentiation-enhanced binding of the aminoterminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA, 1985, 82(15), 4939-4943.
27. Vassalli, J.D.; Baccino, D.; Belin, D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol., 1985, 100(1), 86-92. (Pubitemid 15151884)
28. Nielsen, L.S.; Kellerman, G.M.; Behrendt, N.; Picone, R.; Danø, K.; Blasi, F. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J. Biol. Chem., 1988, 263(5), 2358-2363.
29. Pass, J.; Jögi, A.; Lund, I.K.; Rønø, B.; Rasch, M.G.; Gårdsvoll, H.; Lund, L.R.; Ploug, M.; Rømer, J.; Danø, K.; Høyer-Hansen, G. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: Inhibitory effects on receptor mediated uPA activity in vitro and in vivo. Thromb. Haemost., 2007, 97(6), 1013-1022.
30. Quax, P.H.; Lamfers, M.L.; Lardenoye, J.H.; Grimbergen, J.M.; de Vries, M.R.; Slomp, J.; de Ruiter, M.C.; Kockx, M.M.; Verheijen, J.H.; van Hinsbergh, V.W. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation, 2001, 103(4), 562-569.
31. Kobayashi, H.; Sugino, D.; She, M. Y.; Ohi, H.; Hirashima, Y.; Shinohara, H.; Fujie, M.; Shibata, K.; Terao, T. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Eur. J. Biochem., 1998, 253(3), 817-826.
32. Muehlenweg, B.; Assfalg-Machleidt, I.; Parrado, S.G.; Burgle, M.; Creutzburg, S.; Schmitt, M.; Auerswald, E.A.; Machleidt, W.; Magdolen, V. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site. J. Biol. Chem., 2000, 275(43), 33562-33566.
33. Goodson, R.J.; Doyle, M.V.; Kaufman, S.E.; Rosenberg, S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA, 1994, 91(15), 7129-7133.
34. Jorgensen, T.J.; Gardsvoll, H.; Dano, K.; Roepstorff, P.; Ploug, M. Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry. Biochemistry, 2004, 43(47), 15044-15057. (Pubitemid 39587481)
35. Ploug, M.; Ostergaard, S.; Gardsvoll, H.; Kovalski, K.; Holst- Hansen, C.; Holm, A.; Ossowski, L.; Dano, K. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry, 2001, 40(40), 12157-12168. (Pubitemid 32946557)
36. Burgle, M.; Koppitz, M.; Riemer, C.; Kessler, H.; Konig, B.; Weidle, U.H.; Kellermann, J.; Lottspeich, F.; Graeff, H.; Schmitt, M.; Goretzki, L.; Reuning, U.; Wilhelm, O.; Magdolen, V. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biol. Chem., 1997, 378(3-4), 231-237.
37. Magdolen, V.; Burgle, M.; de Prada, N. A.; Schmiedeberg, N.; Riemer, C.; Schroeck, F.; Kellermann, J.; Degitz, K.; Wilhelm, O.G.; Schmitt, M.; Kessler, H. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol. Chem., 2001, 382(8), 1197-1205.
38. Schmiedeberg, N.; Schmitt, M.; Rolz, C.; Truffault, V.; Sukopp, M.; Burgle, M.; Wilhelm, O.G.; Schmalix, W.; Magdolen, V.; Kessler, H. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics. J. Med. Chem., 2002, 45(23), 4984-4994.
39. Rosenberg, S. New developments in the urokinase-type plasminogen activator system. Expert Opin. Ther. Targets, 2001, 5(6), 711-722.
40. Ploug, M.; Ostergaard, S.; Hansen, L.B.; Holm, A.; Dano, K. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist: evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry, 1998, 37(11), 3612-3622. (Pubitemid 28162916)
41. Knor, S.; Sato, S.; Huber, T.; Morgenstern, A.; Bruchertseifer, F.; Schmitt, M.; Kessler, H.; Senekowitsch-Schmidtke, R.; Magdolen, V.; Seidl, C. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(1), 53-64.
42. Sato, S.; Kopitz, C.; Schmalix, W.A.; Muehlenweg, B.; Kessler, H.; Schmitt, M.; Kruger, A.; Magdolen, V. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett., 2002, 528(1-3), 212-216. (Pubitemid 35258026)
43. Ploug, M.; Ronne, E.; Behrendt, N.; Jensen, A.L.; Blasi, F.; Dano, K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J. Biol. Chem., 1991, 266(3), 1926-1933.
44. Llinas, P.; Le Du, M.H.; Gardsvoll, H.; Dano, K.; Ploug, M.; Gilquin, B.; Stura, E.A.; Menez, A. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J., 2005, 24(9), 1655-1663. (Pubitemid 40704976)
45. Engelholm, L.H.; Behrendt, N. Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterization of the receptor in four primate species. Biol. Chem., 2001, 382(3), 435-442.
46. Wei, Y.; Waltz, D.A.; Rao, N.; Drummond, R.J.; Rosenberg, S.; Chapman, H.A. Identification of the Urokinase Receptor as All Adhesion Receptor for Vitronectin. J. Biol. Chem., 1994, 269(51), 32380-32388.
47. Huai, Q.; Zhou, A.; Lin, L.; Mazar, A.P.; Parry, G.C.; Callahan, J.; Shaw, D.E.; Furie, B.; Furie, B.C.; Huang, M. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat. Struct. Mol. Biol., 2008, 15(4), 422-423.
48. Gardsvoll, H.; Ploug, M. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J. Biol. Chem., 2007, 282 (18), 13561-13572.
49. Huai, Q.; Mazar, A.P.; Kuo, A.; Parry, G.C.; Shaw, D.E.; Callahan, J.; Li, Y.; Yuan, C.; Bian, C.; Chen, L.; Furie, B.; Furie, B.C.; Cines, D.B.; Huang, M. Structure of human urokinase plasminogen activator in complex with its receptor. Science, 2006, 311(5761), 656-659. (Pubitemid 43191309)
50. Huang, M.D.; Mazar, A.P.; Parry, G.; Higazi, A.A.; Kuo, A.; Cines, D.B. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143). Acta Crystallogr. D. Biol. Crystallogr., 2005, 61, 697-700.
51. Yuan, C.; Huai, Q.; Bian, C.B.; Huang, M. The expression, purification and crystallization of monomeric soluble human urokinase receptor. Prog. Biochem. Biophys., 2006, 33, 277-281.
52. Yuan, C.; Huang, M. Does the urokinase receptor exist in a latent form? Cell Mol. Life Sci., 2007, 64(9), 1033-1037. (Pubitemid 46684549)
53. Oprea, T.I.; Bologa, C.G.; Edwards, B.S.; Prossnitz, E.R.; Sklar, L.A. Post-high-throughput screening analysis: an empirical compound prioritization scheme. J. Biomol. Screen, 2005, 10(5), 419-426.
54. Hann, M.M.; Oprea, T.I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol., 2004, 8(3), 255-263.